A toxic antibody is the latest weapon that promises promise as a broad spectrum treatment for many types of advanced cancer.
Presented a & # 39; Trojan horse & # 39; Chemotherapy strategy, the new drug has proven itself to be eligible for the transfer of chains of clinical trials that are being evaluated to a wider variety of patients. This is not a cure – all this, but this approach is closer to & # 39; t we get.
Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have tried new treatments in a clinical trial involving 147 patients to evaluate their possible benefits and risk of side effects.
Called tisotumab vedotin, or the TV is for short, the drug is made up of a monoclonal antibody, and a cytotoxic substance that can damage cells.
The antibody, if you like, is a stunning gift horse at the door of the enemy ̵
As all types of healthy cells have this cause, different types of tumors are exploited as a way to grow in control, making it an impressive target for cytotoxic seek- and-destroy chemical weapons.
In this case, the substance assigned to this task of killing is monomethyl auristatin E, a molecule that prevents cells from recovering.
"What is exciting in this treatment The mechanism of action is completely novel – it acts like a Trojan horse to get out of cancer cells and eliminate them from within," says oncologist Johann de Bono from The Institute of Cancer Research.
"Our early studies have shown that it is potentially to treat a large number of different types of cancer, and especially some with a low rate of safety . "
Combinated cervical, bladder, endometrium, esophagus, and lung cancer.
Bladder cancer has seen the most remarkable response, with 27 percent of volunteers enrolled seeing their stabilized disease. At the other end is endometrial cancer, with a modest 7 percent improvement in subjects.
"It's a pleasure to see TV-enabled potentials for different cancers," says The Institute of Cancer Research's Chief Executive, Paul Workman.
"I look forward to looking at clinical progress and hope it can benefit patients who are currently operating on treatment options."
This development is slow. Clinical trials started in Phase I in 2013 on TV safety testing in 27 patients.
After a year and a half, serious health problems have emerged, including signs of severe diabetes, mucous inflammation, and fever.
Lower doses have been seen about side-effects that have dropped, although treatment is still far from trouble, with nosebleed, nausea, and fatigue in common complaints.
However, when it is a question of life or death, non-life-threatening illnesses such as these may seem worthless in comparison. Phase I testing gave way to phase II, which shows that TV can make a big difference to many patients with cancer that others will do.
"TV has a timely effect, and we have seen some good responses to patients in our trials, which all have late-stage cancer that have been very widely treated with other drugs and have run out Other options, "says de Bono.
The next step is to expand the second part of the test to include bowel and pancreas cancer, while testing it as a second-line drug for cervical cancers who have failed to die after the first treatments.
It's important to remember that this is not a cure for everyone, or the end of the cancer as we know it. But when so many great treatments do not work beyond the starting line, the promise of one can make a difference between different types of advanced cancer is exciting.
If all is good, we can expect a third stage of the test for several years, where the drug and safety effectiveness is compared to similar treatments.
Everyone needs time and money, so we do not expect TV to be available within a few hours (if at all). But it represents the success of an old military strategy applied to a cancer-fighting drug that is great for treatment of its kind.
"It is very difficult for us to develop modern treatments such as this one that can cure cancer in new ways, and remain effective even against tumors that have been resistant to common therapies," says Workman .
This research was published in The Lancet Oncology .